← FDA DRUG APPROVALS

FDA NDA · NDA210923

MULPLETA

lusutrombopag

Sponsor: VANCOCIN ITALIA

APPLICATION
NDA210923
TYPE
NDA
ORIGINAL APPROVAL
2018-07-31
LATEST ACTION
2018-07-31
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MULPLETA · ReferencePrescription
LUSUTROMBOPAG 3MG · TABLET · ORAL

Approval history

2018-07-31Type 1 - New Molecular Entity · Original · priority — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →